Status:
COMPLETED
Individual Differences in Drug Response
Lead Sponsor:
University of Chicago
Conditions:
Differential Female Response to Δ9-tetrahydrocannabinol (THC)
Eligibility:
FEMALE
18-35 years
Phase:
EARLY_PHASE1
Brief Summary
Females are increasingly using cannabis, yet remain underrepresented in preclinical and clinical cannabinoid research. This female-specific research plan will test the effects of two recreationally re...
Eligibility Criteria
Inclusion
- 18-35 years old, females (N=60)
- Body Mass Index 19-26
- High school education, fluent in English
- Occasional cannabis users ( \<11 times in past 30 days)
Exclusion
- History of daily cannabis use
- Past or present severe substance use disorder
- Current or past diagnosis with drug treatment for psychosis/bipolar/schizophrenia
- Past year major depression
- Current or past Post Traumatic Stress Disorder
- Attention Deficit Hyperactivity Disorder
- Cardiovascular illness, high blood pressure, abnormal electrocardiagram
- Current medications (NO hormonal birth control or intrauterine device)
- Pregnant or planning to become pregnant
Key Trial Info
Start Date :
November 6 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03809546
Start Date
November 6 2018
End Date
June 1 2021
Last Update
July 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60615